slides · global inventory
Table
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 60,568
Current window 37,831-37,860
Pages 2,019
Rows per page 30
Component
37,831-37,860 of 60,568
12
The slide includes a specific footnote regarding FY21 capital expenditures related to a manufacturing operation in Turkey.Lindsay Corporation | Results Presentation Deck | 17 slides · Lindsay Corporation
Conference presentation Investor relations Beat · VisualizationLoop · Logic Chain1 hit
16
LVMH | Results Presentation Deck | 28 slidesLVMH | Results Presentation Deck | 28 slides · LVMH
Conference presentation Investor relations Loop · Logic Chain1 hit
19
Slide 19 from an LVMH Q3 2022 revenue presentation.LVMH | Results Presentation Deck | 28 slides · LVMH
Conference presentation Investor relations Loop · Logic Chain1 hit
27
The table uses 'x 2,2' to denote growth multipliers for specific periods in 2021.LVMH | Results Presentation Deck | 28 slides · LVMH
Conference presentation Investor relations 1 hit
07
MainStreet Bancshares | Results Presentation Deck | 31 slidesMainStreet Bancshares | Results Presentation Deck | 31 slides · MainStreet Bancshares, Inc.
Conference presentation Investor relations Beat · NeedLoop · Logic Chain1 hit
09
The chart uses a stacked bar format to distinguish between general non-interest income and swap fee income.MainStreet Bancshares | Results Presentation Deck | 31 slides · MainStreet Bancshares, Inc.
Conference presentation Investor relations Beat · NeedLoop · Logic Chain1 hit
15
The table reconciles beginning net loans to ending net loans, adjusting for new loans, repayments, fees, ALLL, and PPP loans.MainStreet Bancshares | Results Presentation Deck | 31 slides · MainStreet Bancshares, Inc.
Conference presentation Investor relations Beat · Satisfaction1 hit
18
Includes a table of credit quality ratios and non-performing assets, a bar chart of loss reserves, and two line charts showing NPAs/Assets and ALLL/Gross Loans.MainStreet Bancshares | Results Presentation Deck | 31 slides · MainStreet Bancshares, Inc.
Conference presentation Investor relations Beat · Satisfaction1 hit
19
The slide highlights the cost and structure of subordinated debt as a component of the holding company's capital stack.MainStreet Bancshares | Results Presentation Deck | 31 slides · MainStreet Bancshares, Inc.
Conference presentation Investor relations Beat · Satisfaction1 hit
27
The table includes GAAP and Non-GAAP metrics, including core adjustments and balance sheet averages.MainStreet Bancshares | Results Presentation Deck | 31 slides · MainStreet Bancshares, Inc.
Conference presentation Investor relations Beat · Action1 hit
28
The table includes both GAAP and Non-GAAP financial measures.MainStreet Bancshares | Results Presentation Deck | 31 slides · MainStreet Bancshares, Inc.
Conference presentation Investor relations Beat · Action1 hit
08
The slide uses a checkmark/cross system to visually demonstrate the superiority of LNCs.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
09
The slide uses a Gantt-style chart to map drug programs against development stages.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
14
The slide details the dosing regimens for different cohorts over induction and consolidation phases.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
23
The slide uses a map of the US to anchor the revenue projection and a list of four comparable deals to establish market precedent.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Market Sizing1 hit
30
Uses checkmarks for completed items and circular arrows for upcoming/potential items.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
04
The slide presents preliminary financial data for the third quarter of 2022, including income statement components and key balance sheet items.Matson | Results Presentation Deck | 10 slides · Matson
Conference presentation Investor relations 1 hit
04
The slide details a strategic partnership involving equity investment and asset licensing.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations 1 hit
06
The slide uses a Gantt-style visualization to map drug development stages against specific clinical indications and future catalysts.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations 1 hit
12
Includes definitions for abbreviations and source citations.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
13
NASH (Non-Alcoholic Steatohepatitis); NAFLD (Non-Alcoholic Fatty Liver Disease); T2DM (Type 2 Diabetes Mellitus); FPFV (First Patient First Visit); LPLV (Last Patient Last Visit).NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
20
NASH (Non-Alcoholic Steatohepatitis); MAD (Multiple Ascending Dose); SAD (Single Ascending Dose); PK (Pharmacokinetic); PD (Pharmacodynamic); FPFV (First Patient First Visit); LPLV (Last Patient Last Visit).NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
25
The slide uses a 'before-after' style comparison to show the potential market cap uplift for NeuroBo's assets compared to current peer valuations.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations 1 hit
26
Includes footnotes regarding anti-dilution provisions and Dong-A license agreement terms.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · Financials1 hit
28
The slide details the IP ownership status and patent expiration timelines for two specific drug candidates.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations 1 hit
05
The slide uses a matrix-like structure to compare drug capabilities against specific clinical requirements.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations 1 hit
11
The slide outlines the clinical trial structure, including patient eligibility criteria and study objectives for both phases.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
13
The slide presents baseline patient characteristics and prior treatment history for a clinical trial cohort.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
14
Data presented at ENA 2022. N=35 patients.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
16
Clinical trial data presentation for ENA 2022.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations Loop · Cost Of Inaction1 hit